Tyra Biosciences Prices $400 Million Public Offering

Key Facts

1Tyra Biosciences announced the pricing of an underwritten offering of common stock and pre-funded warrants to raise $400 million.

2The offering price was set at $22.03 per share of common stock.

In a move reflecting the high capital requirements of clinical-stage research, Tyra Biosciences has announced the pricing of an underwritten public offering of common stock and pre-funded warrants to raise $400 million. The offering price was set at $22.03 per share of common stock, consisting of approximately 9.08 million shares and an equal number of pre-funded warrants. The company intends to utilize the proceeds to fund the development of its precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.

Per market data, TYRA shares closed at $22.03 on September 11, 2026, aligning exactly with the announced offering price. During that trading session, the stock reached a high of $23.96 and a low of $21.86. This capital raise is a strategic step for the clinical-stage biotech firm to secure R&D funding, although such large equity offerings typically introduce short-term dilution concerns for existing shareholders.

With the stock at $22.03 as of the close on September 11, 2026, investors will be watching for price stability around this benchmark as the new shares enter the market. Given the absence of immediate sector-specific catalysts in the upcoming economic calendar, the primary driver for the stock in the near term will likely be the market's absorption of this significant liquidity injection and its impact on the company's valuation.